# Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

> **NCT03813836** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 63 (actual)

## Conditions studied

- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03813836
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-05
- **Primary completion:** 2024-01-10
- **Final completion:** 2026-01-31
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813836, "Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03813836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*